6 Analysts Have This To Say About Corcept Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past three months, six analysts have evaluated Corcept Therapeutics (NASDAQ:CORT), with all ratings being bullish. The average 12-month price target has increased by 6.27% to $48.67. Analysts from Truist Securities and HC Wainwright & Co. have maintained or raised their buy ratings, reflecting positive sentiment. Corcept Therapeutics has shown strong financial performance with significant revenue growth, high net margins, and efficient asset management.
June 17, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Corcept Therapeutics has received exclusively bullish ratings from six analysts over the past three months. The average 12-month price target has increased by 6.27% to $48.67, with high estimates reaching $65.00. Analysts from Truist Securities and HC Wainwright & Co. have maintained or raised their buy ratings, indicating strong confidence in the company's future performance. Corcept Therapeutics has also demonstrated robust financial health with significant revenue growth, high net margins, and efficient asset management.
The unanimous bullish ratings from six analysts and the increase in the average price target indicate strong positive sentiment towards Corcept Therapeutics. The company's robust financial performance, including significant revenue growth and high net margins, further supports the positive outlook. The maintained and raised buy ratings from reputable firms like Truist Securities and HC Wainwright & Co. add to the confidence in the company's future performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100